News Novartis builds in cardiovascular with $3.1bn Anthos buy Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
News US/EU regulators start review of Biogen's high-dose Spinraza Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?
News New data could widen use of Novartis' SMA therapy Zolgensma Phase 3 results with an intrathecal version of Novartis spinal muscular atrophy (SMA) gene therapy could make older children eligible for treatment.
News Novartis sheds MorphoSys staff, sites after pelabresib delay Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year.
News ICER identifies new crop of 'unsupported' drug price rises Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.
Oncology Can CAR-T first movers keep pace in a rapidly evolving marke... The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market.
News FDA chooses flu vaccine strains despite cancelled meeting The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season – without the input of its external advisors.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl